한빛사논문 | BRIC

조병철 님의 논문 목록

연세대학교 의과대학

CV File 1 MB

- 조병철(연세대학교 의과대학)
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
- N. Engl. J. Med., Jun 26 2024, | https://doi.org/10.1056/NEJMoa2403614
- 2024-06
- 의약학
- 한빛사논문
D3S-001, a KRAS G12C inhibitor with rapid target engagement kinetics, overcomes nucleotide cycling and demonstrates robust preclinical and clinical activities
- Cancer Discov., May 08 2024, | https://doi.org/10.1158/2159-8290.CD-24-0006
- 2024-05
- 의약학
- 한빛사논문
Discovery of a novel potent EGFR inhibitor against EGFR activating mutations and on-target resistance in NSCLC
- Clin. Cancer Res., Feb 08 2024, | https://doi.org/10.1158/1078-0432.CCR-23-2951
- 2024-02
- 의약학
- 한빛사논문
- 조병철(연세대학교 의과대학)
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
- N. Engl. J. Med., Jan 11 2024, 390 (2) | https://doi.org/10.1056/NEJMoa2302299
- 2024-01
- 의약학
- 한빛사논문
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
- JAMA Oncol., Sep 28 2023, e233867 | https://doi.org/10.1001/jamaoncol.2023.3867
- 2023-09
- 의약학
- 한빛사논문
- 조병철(연세대학교 의과대학)
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
- Nat. Med., 14 September 2023 | https://doi.org/10.1038/s41591-023-02554-7
- 2023-09
- 의약학
- 한빛사논문
- 조병철(연세대학교 의과대학)
Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial.
- J. Thorac. Oncol., Aug 17 2023, S1556-0864(23)00738-4 | https://doi.org/10.1016/j.jtho.2023.08.018
- 2023-08
- 의약학
- 한빛사논문
- 조병철(연세대학교 의과대학)
Lazertinib Versus Gefitinib as First-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer (NSCLC): Results From LASER301
- J. Clin. Oncol., 2023 Jun 28;101200JCO2300515 | DOI: 10.1200/JCO.23.00515
- 2023-06
- 의약학
- 한빛사논문
- 조병철(연세대학교 의과대학)
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
- Lancet Oncol., Volume 23, Issue 6, June 2022, Pages 781-792 | https://doi.org/10.1016/S1470-2045(22)00226-1
- 2022-06
- 의약학
- 한빛사논문
[In the Spotlight]Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC
- Cancer Discov., Published January 2022 | DOI: 10.1158/2159-8290.CD-21-1429
- 2022-01
- 의약학
- 한빛사논문

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기